Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options for 4,302 shares of common stock at strike prices of $7.14 and $9.08 per share, then sold 4,302 shares in open-market transactions on June 17, 2026 at weighted average prices around $110–$112 per share. The filing shows these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2025. Following the sales, she holds 0 shares of Palvella common stock directly, and no remaining option positions are listed in this filing.
Palvella Therapeutics submitted a Form 144 notice indicating proposed sale activity in its Common Stock via a stock option exercise on 06/17/2026. The filing lists a transaction value of $476,372.94 and references Nasdaq as the market.
The excerpt also shows three prior reported sales by Kathleen Goin during the past three months with values of $507,611.05, $547,398.96 and $475,630.84. The filing identifies the broker address for Piper Sandler & Co.
Palvella Therapeutics CFO Matthew E. Korenberg exercised stock options to acquire 1,000 shares of common stock at $13.60 per share. Following the transaction, he directly owns 1,000 common shares and retains stock options covering 166,100 shares.
The exercised options have an exercise price of $13.60 and an expiration date of December 13, 2034. According to the vesting terms, 25% of the options vest on October 16, 2025, with the remaining 75% vesting in equal monthly tranches over the next 36 months.
Palvella Therapeutics, Inc. stockholders approved an amendment to the company’s 2024 Equity Incentive Plan, increasing the authorized shares issuable under the plan by 750,000 shares. This amendment had been previously approved by the Board of Directors, subject to stockholder approval, and became effective immediately at the 2026 Annual Meeting.
As of April 13, 2026, there were 14,323,686 outstanding common shares entitled to vote. Stockholders elected three Class III directors—George M. Jenkins, Todd C. Davis and John Doux, M.D.—to serve until the 2029 Annual Meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers and chose to hold future advisory votes on executive compensation every year. They approved both the equity plan amendment and a potential adjournment proposal, although adjournment was ultimately unnecessary.
PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share. These options expire on June 10, 2036 and vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director George M. Jenkins received a grant of stock options for 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. They vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, subject to his continued service. After this grant, he holds 3,000 options directly.
Palvella Therapeutics director Elaine J. Heron received a grant of stock options for 3,000 shares of common stock. These options carry an exercise price of $102.19 per share and expire on June 10, 2036.
The options vest upon the earlier of the first anniversary of the June 10, 2026 grant date or the company’s next annual meeting of stockholders, subject to Heron’s continued service through the applicable vesting date. Following this grant, Heron holds 3,000 stock options directly.
PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of 102.1900 per share and expire on 2036-06-10.
These options vest upon the earlier of the first anniversary of the 2026-06-10 grant date or the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related grant, Doux holds 3,000 stock options directly.
Palvella Therapeutics director Todd C. Davis received a new stock option grant. He was awarded options to buy 3,000 shares of common stock at an exercise price of $102.19 per share, expiring on June 10, 2036. The options vest on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. All 3,000 options are held directly after this transaction. The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual meeting of stockholders, in each case requiring his continued service through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.